Trial
NCT01206101
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Diabetes
Intervention
liraglutide
Why stopped
The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well as challenges relating to trial execution and study completion.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-30